Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan;206(1):375-377.
doi: 10.1111/bjh.19861. Epub 2024 Nov 3.

A second chance for avatrombopag in chemotherapy-induced thrombocytopenia

Hanny Al-Samkari  1   2 , Donald C Moore  3
Affiliations

A second chance for avatrombopag in chemotherapy-induced thrombocytopenia

Hanny Al-Samkari et al. Br J Haematol. 2025 Jan.

Abstract

Chemotherapy-induced thrombocytopenia (CIT) remains a common complication of cancer therapy with no approved available treatments in most of the world. Although a prior clinical trial of avatrombopag for CIT did not meet its primary end-point, a report from Galamaga and colleagues raises prospects for a second chance for avatrombopag in CIT, highlighting the differences between nadir and persistent CIT and the importance of patient selection in CIT treatment. Commentary on: Galamaga et al. Avatrombopag for the treatment of patients with chemotherapy-induced thrombocytopenia: a case series. Br J Haematol 2025; 206:272-278.

Keywords: avatrombopag; chemotherapy‐induced thrombocytopenia; persistent; romiplostim; thrombopoietin receptor agonist.

PubMed Disclaimer

References

REFERENCES

    1. Galamaga R, Johnson S, Acosta C. Avatrombopag for the treatment of patients with chemotherapy‐induced thrombocytopenia: a case series. Br J Haematol. 2025;206(1):272–278.
    1. Al‐Samkari H, Soff GA. Clinical challenges and promising therapies for chemotherapy‐induced thrombocytopenia. Expert Rev Hematol. 2021;14(5):437–448.
    1. Al‐Samkari H. Optimal management of chemotherapy‐induced thrombocytopenia with thrombopoietin receptor agonists. Blood Rev. 2024;63:101139.
    1. Al‐Samkari H, Marshall AL, Goodarzi K, Kuter DJ. The use of romiplostim in treating chemotherapy‐induced thrombocytopenia in patients with solid tumors. Haematologica. 2018;103(4):e169–e172.
    1. Al‐Samkari H, Parnes AD, Goodarzi K, Weitzman JI, Connors JM, Kuter DJ. A multicenter study of romiplostim for chemotherapy‐induced thrombocytopenia in solid tumors and hematologic malignancies. Haematologica. 2021;106(4):1148–1157.

LinkOut - more resources